Jamal Tarazi
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 23
-
- Renal cell carcinoma treatment 43
- Lung Cancer Treatments and Mutations 10
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 9
- Colorectal Cancer Treatments and Studies 8
- Pancreatic and Hepatic Oncology Research 8
- Molecular Biology top 5%
- Renal and related cancers 17
- Hepatology top 10%
-
- Economic and Financial Impacts of Cancer 16
Jamal Tarazi
64 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 73
- Cancer Research 960
- Pulmonary and Respiratory Medicine 2.0k
- Oncology 1.0k
- Molecular Biology 1.4k
- Hepatology 84
Countries citing papers authored by Jamal Tarazi
This map shows the geographic impact of Jamal Tarazi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamal Tarazi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamal Tarazi more than expected).
Fields of papers citing papers by Jamal Tarazi
This network shows the impact of papers produced by Jamal Tarazi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamal Tarazi. The network helps show where Jamal Tarazi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jamal Tarazi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 0 | |
| 3 | Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancerbreakdown → | 2023 | 114 |
| 4 | 2021 | 21 | |
| 5 | 2020 | 16 | |
| 6 | 2019 | 11 | |
| 7 | Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialbreakdown → | 2018 | 274 |
| 8 | 2016 | 2 | |
| 9 | 2016 | 3 | |
| 10 | 2016 | 26 | |
| 11 | 2015 | 29 | |
| 12 | 2015 | 23 | |
| 13 | 2015 | 18 | |
| 14 | 2013 | 67 | |
| 15 | 2013 | 117 | |
| 16 | 2012 | 21 | |
| 17 | 2011 | 5 | |
| 18 | 2009 | 50 | |
| 19 | 2008 | 29 | |
| 20 | Axitinib (AG-013736; AG) in combination with paclitaxel (P)/carboplatin (C) in patients (pts) with advanced solid tumors | 2007 | 1 |
About Jamal Tarazi
Jamal Tarazi is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology, having authored 65 papers that have together received 2.6k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (43 papers), Cancer Genomics and Diagnostics (23 papers), Renal and related cancers (17 papers), Economic and Financial Impacts of Cancer (16 papers), Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (9 papers), Colorectal Cancer Treatments and Studies (8 papers) and Pancreatic and Hepatic Oncology Research (8 papers). The work is most often cited by research in Cancer Research (960 citations), Pulmonary and Respiratory Medicine (2.0k citations) and Oncology (1.0k citations). Jamal Tarazi has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Brad Rosbrook, Brian I. Rini, Sinil Kim, Robert J. Motzer, Bernard Escudier, Walter M. Stadler, Janice P. Dutcher, Thomas E. Hutson, George Wilding and Piotr Tomczak. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.